Person: KARADAĞ, MEHMET
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KARADAĞ
First Name
MEHMET
Name
48 results
Search Results
Now showing 1 - 10 of 48
Publication The relationship between serum periostin levels, 6-minute walking test and quality of life in patients with idiopathic pulmonary fibrosis(Carbone Editore, 2019-01-01) Eken, Özge Aslantekin; ASLANTEKİN EKEN, ÖZGE; Coşkun, Funda; COŞKUN, NECMİYE FUNDA; Demirdöğen, Ezgi; DEMİRDÖĞEN, EZGİ; Dilektaşlı, Aslı Görek; GÖREK DİLEKTAŞLI, ASLI; Ursavaş, Ahmet; URSAVAŞ, AHMET; Budak, Ferah; BUDAK, FERAH; Karadağ, Mehmet; KARADAĞ, MEHMET; Tıp Fakültesi; İmmunoloji Ana Bilim Dalı; 0000-0003-3604-8826; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0001-7625-9148; 0000-0002-9027-1132; AAG-8744-2021; AAI-3169-2021; JPK-7012-2023; AAD-1271-2019; IZP-9398-2023; F-4657-2014; AAH-9812-2021Introduction: Interstitial lung disease (ILD) is a group of chronic respiratory diseases characterized by inflammation and fi-brosis in different patterns at the interstitium, which is the most common form of idiopathic pulmonary fibrosis (IPF). Considering the prevalence, incidence, and outcomes of IPF, it is important to ensure the availability and validity of biomarkers that can be used in determining the diagnosis and prognosis. In this study, we aimed to assess the relationship between serum periostin levels, pulmonary function tests, 6-minute walking test (6MWT) and quality of life in IPF patients.Material and methods: Our study was carried out with 40 IPF patients who were followed at Uludag University, Faculty of Medicine, Department of Pulmonary Medicine. Spirometer and carbon monoxide diffusion test (DLCO) for respiratory functions, 6MWT and periostin level measurement were performed on the patients, and results were recorded.Results: A total of 31 of patients were males and nine were females. The diagnosis of IPF was made according to the guidelines of ATS / ERS / JRS / ALAT with 25 (62.5%) patients by radiologically and 15 (37.5%) patients with histopathological and radiological features. The mean periostin level was 32.9 +/- 37.57 ng/ml. No significant correlation was found between St. George's Respiratory Questionnaire (SGRQ) score, FVC% predicted, DLCO adj% predicted values, 6MWT distance and periostin level which were measured simultaneously. A negative correlation was found between SGRQ score and DLCO adj% predicted value, 6MWT distance.Conclusion: It has been shown that there is no correlation between periostin levels and the results of the pulmonary function tests, when measured and performed at the same time. No studies are evaluating the relationship between 6MWT and SGRQ scores and periostin levels. In our study, serum periostin level, pulmonary function test results, 6MWT and SGRQ scores were not significantly correlated.Publication Association of fatigue with mental well-being, quality of life and exercise capacity in sarcoidosis: A case-control comparision(Amer, 2015-01-01) Dilektaşlı, Aslı Görek; Çetinoğlu, E. Demirdöğen; Acet, N. Aylin; Gökmen, Nilüfer E.; Karadağ, Mehmet; Uzaslan, Esra; GÖREK DİLEKTAŞLI, ASLI; Çetinoğlu, E. Demirdöğen; ACET ÖZTÜRK, NİLÜFER AYLİN; KARADAĞ, MEHMET; UZASLAN, AYŞE ESRA; Tıp Fakültesi; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0002-6375-1472; 0000-0002-9027-1132; Z-1424-2019; JPK-7012-2023; AAG-8744-2021; DTT-7416-2022; AAH-9812-2021; Z-1424-2019; CQV-5946-2022; CDI-1977-2022Publication Frailty: An indicator for poor outcomes among in-hospital pulmonology patients(European Respiratory Soc Journals, 2021-09-05) Öztürk, Nilüfer Aylin Acet; Dilektaşlı, Aslı Görek; Güçlü, Özge Aydın; Ursavaş, Ahmet; Demirdoğen, Ezgi; Coşkun, Funda; Uzaslan, Esra; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; GÖREK DİLEKTAŞLI, ASLI; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; DEMİRDÖĞEN, EZGİ; COŞKUN, NECMİYE FUNDA; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Tıp Fakültesi; Göğüs Hastalıkları Ana Bilim Dalı; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0002-9027-1132; AAI-3169-2021; JPK-7012-2023; AAG-8744-2021; AAD-1271-2019; Z-1424-2019; CNP-1063-2022; AAG-9930-2019; CDI-1977-2022Publication Evaluation of fibrinogen levels in patients with obstructive sleep apnea syndrome(Wiley, 2013-11-01) Çetinoğlu, Ezgi Demirdoğen; Ursavaş, Ahmet; Karadağ, Mehmet; Coşkun, Funda; Ediger, Dane; Uzaslan, Esra; Ege, Ercüment; Gözü, Oktay; Çetinoğlu, Ezgi Demirdoğen; URSAVAŞ, AHMET; KARADAĞ, MEHMET; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; UZASLAN, AYŞE ESRA; Ege, Ercüment; Gözü, Oktay; Tıp Fakültesi; Göğüs Hastalıkları Ana Bilim Dalı; 0000-0002-7400-9089; 0000-0002-9027-1132; 0000-0003-3604-8826; 0000-0002-2954-4293; AAI-3169-2021; AAD-1271-2019; AAG-8744-2021; JPK-7012-2023; AAE-9142-2019; AAH-9812-2021; CDI-1977-2022; CPF-5844-2022; JLC-5863-2023Publication Coexistence of sarcoidosis and sjogren's syndrome: A case-report(Amer, 2015-10-01) Dilektaşlı, Aslı Görek; Çetinoğlu, Ezgi Demirdoğen; Durmuş, Eda; Uzaslan, Esra; Ege, Ercüment; Karadağ, Mehmet; GÖREK DİLEKTAŞLI, ASLI; Çetinoğlu, Ezgi Demirdoğen; Durmuş, Eda; UZASLAN, AYŞE ESRA; Ege, Ercüment; KARADAĞ, MEHMET; Tıp Fakültesi; Göğüs Hastalıkları Ana Bilim Dalı; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0002-9027-1132; AAG-8744-2021; JPK-7012-2023; DTT-7416-2022; ETU-0442-2022; CDI-1977-2022; CPF-5844-2022Publication AVAPS-NIV treatment in hypercapnic respiratory failure with insufficient response to fixed-level PS-NIV(Türk Tüberküloz ve Toraks, 2022-01-01) Öztürk, Nilüfer Aylın Acet; Güçlü, Özge Aydın; Demirdöğen, Ezgi; Dilektaşlı, Asli Görek; Maharramov, Shahriyar; Coşkun, Funda; Uzaslan, Esra; Ursavaş, Ahmet; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; AYDIN GÜÇLÜ, ÖZGE; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; Maharramov, Shahriyar; COŞKUN, NECMİYE FUNDA; UZASLAN, AYŞE ESRA; URSAVAŞ, AHMET; KARADAĞ, MEHMET; Tıp Fakültesi; Göğüs Hastalıkları Ana Bilim Dalı; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-3604-8826; 0000-0002-9027-1132; AAI-3169-2021; AAD-1271-2019; AAG-8744-2021; JPK-7012-2023; DTT-7416-2022; DDT-7334-2022Introduction: Noninvasive ventilation (NIV) for acute hypercapnic respiratory failure (AHRF) is an established treatment modality. Current evidence does not conclude any superiority between fixed pressure support (PS) and aver-age volume-assured pressure support (AVAPS) modes. However, given the ability of rapid PaCO2 decline in AVAPS mode, we hypothesized that COPD patients with AHRF who did not show the desired reduction in PaCO2 with fixed-level PS-NIV might benefit from the AVAPS mode.Materials and Methods: Patients admitted to the non-ICU pulmonary ward with acute exacerbation of COPD (AECOPD) and AHRF were included con-secutively in this observational study. Patients with hypercapnic respiratory failure due to obesity-hypoventilation, neurological diseases, or chest wall deformities were excluded. All patients started NIV treatment with fixed pres-sure support (PS) and patients who did not reach clinical and laboratory stability under PS-NIV treatment were switched to the average volume -as-sured pressure support (AVAPS) mode of NIV.Results: Thirty-five COPD patients with hypercapnic respiratory failure were included. Under PS-NIV treatment, 14 (40%) patients showed a 17.9 (-0.0-29.2) percent change in terms of PaCO2 , meaning no improvement or worsening. Therefore, these patients were treated with AVAPS mode. Arterial PaCO2 and pH levels significantly improved after AVAPS-NIV administration. AVAPS-NIV treatment created a significantly better PaCO2 change rate than using PS-NIV (-11.4 (-22.0 --0.5)vs 8.2 (-5.3-19.5), p= 0.02]. Independent predictors of AVAPS mode requirement were higher Charlson Comorbidity Index (OR= 1.74 (95% CI= 1.02-2.97)] and higher PaCO2 upon admission (OR= 1.18 (95% CI= 1.03-1.35)]. Thirteen (92.8%) patients reaching signif-icant clinical stability with AVAPS-NIV were able to return to fixed-level PS-NIV and maintain acceptable PaCO2 levels.Conclusion: Our study demonstrated that patients can benefit from AVAPS-NIV despite insufficient response to fixed-level PS-NIV.Publication Serum cancer from lung-6: Promising biomarker to differentiate cpfe from ipf(Mattioli 1885, 2022-01-01) Uzaslan, Esra; DEMİRDÖĞEN, EZGİ; UZASLAN, AYŞE ESRA; GÖREK DİLEKTAŞLI, ASLI; ÖZKAYA, GÜVEN; Dilektaşlı, Aslı Görek; Öztürk, Nilüfer Aylin Acet; Karadağ, Mehmet; KARADAĞ, MEHMET; ACET ÖZTÜRK, NİLÜFER AYLİN; YEŞİLBURSA, DİLEK; Yeşilbursa, Dilek; Budak, Ferah; BUDAK, FERAH; Öztürk, Alper; Ursavaş, Ahmet; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; Tıp Fakültesi; Kardiyoloji Ana Bilim Dalı; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0002-6375-1472; 0000-0001-7625-9148; 0000-0003-3604-8826; 0000-0003-0297-846X; 0000-0002-9027-1132; AAD-1271-2019; JPK-7012-2023; IZP-9398-2023; A-4421-2016; F-4657-2014; AAI-3169-2021; AAG-8744-2021Background: Combined pulmonary fibrosis and emphysema (CPFE) has been recognised as a phe-notype of pulmonary fibrosis. We aimed to compare serum surfactant protein-A (SP-A), surfactant protein-D (SP-D) and Krebs von den Lungen-6 (KL-6) levels, functional parameters, in CPFE and IPF (idiopathic pul-monary fibrosis) patients. Methods: Patients diagnosed with ???CPFE??? and ???IPF??? were consecutively included in 6 months as two groups. The patients with connective tissue diseases are excluded. Results: In this study, 47 patients (41 males, 6 females) with CPFE (n = 21) and IPF (n = 26) with a mean age of 70.12 ?? 8.75 were evaluated. CPFE patients were older, had more intense smoking history, had lower DLCO/VA, lower FVC, and worse six-minute walking distance than the IPF group (p=0.005, p=0.027, p=0.02, p<0.001, p=0.001, respec-tively). Serum KL-6 levels were higher in CPFE group compared to IPF group [264.70 U/ml (228.90-786) vs 233.60 (101.8-425.4), p<0.001]. Serum KL-6 levels of 245.4 U/ml and higher have 81% sensitivity and 73% specificity for the discrimination of CPFE from IPF. Conclusions: Our study has shown that serum KL-6 level is a promising biomarker to differentiate CPFE from IPF. In CPFE cases respiratory and functional parameters are worse than those of pure fibrosis cases.Publication Il-21: A potential biomarker for diagnosis and predicting prognosis in covid-19 patients(European Respiratory Society Journals, 2021-09-05) Öztürk, Nilüfer Aylin Acet; Ursavaş, Ahmet; Dilektaşlı, Aslı Görek; Demirdöğen, Ezgi; Coşkun, Funda; Ediger, Dane; Uzaslan, Esra; Yöyen-Ermiş, Diğdem; Karaca, Mert; Terzi, Orkun; Bayram, Merve; Ömer, Dilara; Yiğitliler, Büşra; Yurttaş, Ahmet; Maharramov, Shahriyar; Çelik, Gamze; Oral, Barbaros; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; URSAVAŞ, AHMET; GÖREK DİLEKTAŞLI, ASLI; DEMİRDÖĞEN, EZGİ; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; UZASLAN, AYŞE ESRA; YÖYEN ERMİŞ, DİĞDEM; KARACA, MERT; TERZİ, ORKUN ERAY; BAYRAM, MERVE; ÖMER TOPÇU, DİLARA; YURTTAŞ, AHMET; ORAL, HALUK BARBAROS; KARADAĞ, MEHMET; MAHARRAMOV, SHAHRİYAR; YAZICI, GAMZE; Tıp Fakültesi; 0000-0002-6375-1472; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0002-2954-4293; 0000-0001-5871-8769; 0000-0002-9027-1132; AAG-8744-2021; JPK-7012-2023; AAH-3888-2021; AAE-9142-2019; AAI-3169-2021; AAD-1271-2019Publication Effect of asbestos exposure on the frequency of egfr mutations and alk/ros1 rearrangements in patients with lung adenocarcinoma a multicentric study(Lippincott Williams & Wilkins, 2021-03-01) Yilmaz, Senay; Demirci, Nilgun Yilmaz; Metintas, Selma; Zamani, Adil; Kabalak, Pinar Akin; Yilmaz, Ulku; Ak, Guntulu; Kizilgoz, Derya; Ozturk, Akin; Yilmaz, Ufuk; Batum, Ozgur; Kavas, Murat; Serifoglu, Irem; Unsal, Meftun; Komurcuoglu, Berna E.; Cengiz, Tuba Inal; Ulubay, Gaye; Ozdemirel, Tugce S.; Ozyurek, Berna A.; Kavurgaci, Suna; Alizoroglu, Dursun; Celik, Pinar; Erdogan, Yurdanur; In, Erdal; Aksoy, Asude; Altin, Sedat; Gunluoglu, Gulsah; Metintas, Muzaffer; Karadag, Mehmet; KARADAĞ, MEHMET; Guclu, Ozge A.; AYDIN GÜÇLÜ, ÖZGE; Tıp Fakültesi; 0000-0003-0523-7819; 0000-0001-6160-3778; 0000-0002-9027-1132; 0000-0003-1005-3205; 0000-0001-8849-193X; 0000-0002-3445-3804; 0000-0002-2806-4781; 0000-0002-2877-242X; 0000-0003-1596-0082; 0000-0003-0206-7615; 0000-0002-8807-5853; 0000-0002-5609-9658; HKN-2974-2023; HNT-0352-2023; AAS-6628-2021; AAG-9930-2019; AFT-6588-2022; AET-7187-2022; D-2127-2014; JWA-4269-2024; AFP-3587-2022; HLH-3244-2023; C-9348-2014; AAG-8744-2021Objective: The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations. Methods: Between January 2014 and September 2018, epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), and c-ros oncogene 1 receptor tyrosine kinase gene (ROS1) alterations, demographic characteristics, asbestos exposure, and asbestos-related radiological findings of 1904 patients with lung adenocarcinoma were recorded. Results: The frequencies of EGFR mutations, ALK, and ROS1 rearrangements were 14.5%, 3.7%, and 0.9%, respectively. The rates of EGFR mutations and ALK rearrangements were more frequent in asbestos exposed non-smokers (48.7% and 9%, respectively). EGFR mutation rate was correlated to female gender and not-smoking, ALK rearrangement rate was correlated to younger age, not-smoking, and a history of asbestos exposure. Conclusions: The higher rate of ALK rearrangements in asbestos-exposed lung adenocarcinoma cases shows that asbestos exposure may most likely cause genetic alterations that drive pulmonary adenocarcinogenesis.Publication Understanding university students' smoking behaviors towards tobacco-free campus policy(Turkish Assoc Tuberculosis & Thorax, 2021-01-01) Karadag, Mehmet; Aydin Güçlü, Ozge; Gorek Dilektaşlı, Aslı; Coskun, Funda; Uzaslan, Esra; Gorek Dilektasli, Asli; GÖREK DİLEKTAŞLI, ASLI; Aydin Guclu, Ozge; AYDIN GÜÇLÜ, ÖZGE; Karadag, Mehmet; KARADAĞ, MEHMET; Coskun, Funda; COŞKUN, NECMİYE FUNDA; Uzaslan, Esra; UZASLAN, AYŞE ESRA; Tıp Fakültesi; 0000-0002-9027-1132; 0000-0003-1005-3205; 0000-0001-7099-9647; 0000-0003-3604-8826; AAG-8744-2021; AAG-9930-2019; AAD-1271-2019Introduction: Tobacco-free college campuses refer to colleges and universities that have implemented policies prohibiting the use of tobacco products at all indoor and outdoor campus locations. We aimed to evaluate university students' smoking behaviors and their attitudes towards "Tobacco-Free Campus Policy".Materials and Methods: A total of 10,383 university students were included in this cross-sectional study. The questionnaire was sent via web-based student information system. Demographical variables, the frequency of tobacco use, the addiction levels of the smoker students, and their perspective on the Tobacco-Free Campus Policy were evaluated.Results: The study population consisted of 5461 (52.6%) males and their mean age was 22.1 +/- 3.9 years. Among the students, 3992 (38.4%) were current smokers and the age of first smoking was 16.5 +/- 2.78 years. According to FTND scores, 15.1% of participants have high dependence, and 7.5% of them have very high dependence. There was a significant difference among participants who finds unacceptable "Tobacco-Free Campus Policy" in terms of gender (70.7% males vs. 29.3% females, p< 0.001) and smoking habit (7% never smoker, 4.1% ex-smoker, 88.9% current smoker, p< 0.001).Conclusion: The Tobacco-Free Campus Policy is important to fight against the tobacco industry in order to protect the right to health of all tobacco users and those who do not use it and should be considered as a goal to be achieved in order to live in a healthy environment.